RenovoRx, Inc. (RNXT), a life sciences company, announced Thursday that the U.S. Food and Drug Administration (FDA) recently granted Orphan Drug Designation (ODD) for oxaliplatin for the treatment of pancreatic cancer. Oxaliplatin is an approved and commonly used chemotherapy.
This is RenovoRx's second ODD in pancreatic cancer, and third designation in total, reflecting the Company's differentiated approach to targeted intra-arterial drug-delivery using RenovoCath.
RenovoRx previously received ODD for intra-arterial gemcitabine delivered via RenovoCath in locally advanced pancreatic cancer (LAPC) and bile duct cancer.
This designation for oxaliplatin, a platinum-based chemotherapy widely used in pancreatic cancer treatment, further supports the versatility of RenovoRx's novel approach to delivering multiple therapeutic agents directly near the tumor site.
As RenovoRx continues to advance its therapeutic pipeline, it is simultaneously expanding commercialization of RenovoCath as a stand-alone device, driving adoption at leading cancer centers.
RenovoCath, a patented FDA-cleared device, employs a dual-balloon infusion catheter for targeted delivery of therapeutic agents directly near a tumor.
In Thursday's pre-market trading, RNXT is trading on the Nasdaq at $0.93, down $0.005 or 0.53 percent.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.